

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

Fig. 1 ACA Activity Effect of Serum vs Fish Gelatin




FIGURE 1




FIGURE 2

Immunoreactivity of ACA-6626 with Solid Phase Peptides

- 6626-4A2
- 6626-4G7
- 6626-4B11
- 6626-4C7
- 6626-4D3
- 6501-5A12




FIGURE 3

Serum Crossreactivity of ACA 6501-5A12 Peptide




FIGURE 4

Serum Crossreactivity of ACA 6626-4D3 Peptide




FIGURE 5




FIGURE 6




FIGURE 7

Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND  
METHOD OF TREATMENT FOR APL ANTIBODY-MEDIATED  
PATHOLOGIES

Inventor: Edward Jess VICTORIA, et al.

Application No.: To Be Assigned

Docket No.: 252312006103

Sheet 8 of 32

6501 G-Track of Random Clones

2<sup>nd</sup> Round 3<sup>rd</sup> Round 4<sup>th</sup> Round 5<sup>th</sup> Round c1c2




FIGURE 8

6635 Phage Capture ELISA with HRP- $\alpha$ M13 10.26.94




FIGURE 9

Phage ELISA w/ 6501 Motif Phage 11.9.93




FIGURE 10

Inhibition of (3B10)4 / 6501 Derived by 6501  
Derived Peptide Monomer with 400 Diluted  
Ser. 6501




FIGURE 11

Inhibition of Cdl-2.3%Hu Ser.(no IgG) by  
Modified Peptides 3G3 with 400x Diluted  
Serum 6501




FIGURE 12

Inhibition of (3B10)4 / 6501 Derived by Truncated or  
Non-Truncated 3B10 with 400 Diluted Serum 6501




FIGURE 13

Inhibition of (3B10)4 / 6501 Derived by Alpha MeP 3B10  
Monomer with 400 Diluted Serum 6501




FIGURE 14

# Cross reactivity of peptide LJP 688 with aff-ACA

## Cardiolipin/β2-GPI-coated plates





FIGURE 15

LJP 685-MTU-DABA-PEG. (COMPOUND 36)



mean and S.D. 5 mice/group  
Anti-685, ABC  $\oplus$  10-8M

Figure 16

Treatment groups. Concentration of tolerogen in dish. •  $P=0.0001$

LJP 685-ATU-MTU-AHAB-TEG (COMPOUND 35)




Figure 17




Figure 18

# Solution Structures of Lead ACA Peptides: Cyclic Nine Residue Peptides

5A12

Turn 1: First  
Cys & Disulfide

Turn 2: Sixth  
Ring Amino Acid

3G3

Figure 19

Pharmacophore for binding to anti-cardiolipin antibodies, based on solution structure of DS3G3c (CLGVLA<sup>K</sup>LC) and alanine scanning of this peptide




Figure 20A




Figure 20B

**Inhibition of  $\beta_2$ GP-1 by 6501-Derived Peptides with  
350x Diluted Serum 6501**




FIGURE 21

6701 Titration of CB2\*-F:  
(FITC)-GPCILLARDRCG-CO<sub>2</sub>




FIGURE 22

6501 Titration of CB2\*-F:  
(FITC)-GPCILLARDRCG-CO<sub>2</sub><sup>-</sup>




FIGURE 23




FIGURE 24

Displacement of CB2\*-F from  
6701 using 1.04 eq. of CB2\*:  
GPCILLARDRCG-CO<sub>2</sub><sup>-</sup>




FIGURE 25

CB2\* Titration of CB2\*-F/6701:  
CB2\*: GPCILLARDRCG-CO<sub>2</sub>




FIGURE 26

3B10 Titration of CB2\*-F/6701:  
3B10: AGPCLLLAPDRCPG-CO<sub>2</sub>




FIGURE 27




FIGURE 28




FIGURE 29




FIGURE 30




FIGURE 31




FIGURE 32